Jentashapir Journal of Health Research

Published by: Kowsar

The Diagnostic Value of miR-155 Expression in the Serum of Patients with Breast Cancer According to Molecular Subtypes of Breast Cancer

Bentolhoda Shooshtarian 1 , Javad Mohammadi-Asl 2 , * and Lila Kohan 1
Authors Information
1 Department of Biology, Arsanjan Branch, Islamic Azad University, Arsanjan, IR Iran
2 Cancer, Petroleum and Environmental Pollutants Research Center, Ahvaz Jundishapur University of Medical Sciences (AJUMS), Ahvaz, IR Iran
Article information
  • Jentashapir Journal of Health Research: April 2017, 8 (2); e59937
  • Published Online: April 30, 2017
  • Article Type: Research Article
  • Received: August 8, 2016
  • Revised: January 22, 2017
  • Accepted: February 7, 2017
  • DOI: 10.5812/jjhr.59937

To Cite: Shooshtarian B, Mohammadi-Asl J, Kohan L. The Diagnostic Value of miR-155 Expression in the Serum of Patients with Breast Cancer According to Molecular Subtypes of Breast Cancer, Jundishapur J Helath Res. 2017 ;8(2):e59937. doi: 10.5812/jjhr.59937.

Copyright: Copyright © 2017, Jentashapir Journal of Health Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107. [PubMed: 21296855].
  • 2. Hamilton AM, Aidoudi-Ahmed S, Sharma S, Kotamraju VR, Foster PJ, Sugahara KN, et al. Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain. J Mol Med (Berl). 2015;93(9):991-1001. doi: 10.1007/s00109-015-1279-x. [PubMed: 25869026].
  • 3. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, et al. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 2013;31(25):3083-90. doi: 10.1200/JCO.2012.46.1574. [PubMed: 23897954].
  • 4. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. doi: 10.1038/nature11412. [PubMed: 23000897].
  • 5. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250-63. doi: 10.1093/jnci/djq526. [PubMed: 21191117].
  • 6. Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet. 2009;10(2):94-108. doi: 10.1038/nrg2504. [PubMed: 19148191].
  • 7. Tan G, Tang X, Tang F. The role of microRNAs in nasopharyngeal carcinoma. Tumour Biol. 2015;36(1):69-79. doi: 10.1007/s13277-014-2847-3. [PubMed: 25427638].
  • 8. McManus MT. MicroRNAs and cancer. Semin Cancer Biol. 2003;13(4):253-8. [PubMed: 14563119].
  • 9. Ortiz-Quintero B. Cell-free microRNAs in blood and other body fluids, as cancer biomarkers. Cell Prolif. 2016;49(3):281-303. doi: 10.1111/cpr.12262. [PubMed: 27218664].
  • 10. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207(2):243-9. doi: 10.1002/path.1825. [PubMed: 16041695].
  • 11. Clurman BE, Hayward WS. Multiple proto-oncogene activations in avian leukosis virus-induced lymphomas: evidence for stage-specific events. Mol Cell Biol. 1989;9(6):2657-64. doi: 10.1128/mcb.9.6.2657.
  • 12. Chen J, Wang BC, Tang JH. Clinical significance of microRNA-155 expression in human breast cancer. J Surg Oncol. 2012;106(3):260-6. doi: 10.1002/jso.22153. [PubMed: 22105810].
  • 13. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28(22):6773-84. doi: 10.1128/MCB.00941-08. [PubMed: 18794355].
  • 14. Xiang X, Zhuang X, Ju S, Zhang S, Jiang H, Mu J, et al. miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. Oncogene. 2011;30(31):3440-53. doi: 10.1038/onc.2011.54. [PubMed: 21460854].
  • 15. Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1236-43. doi: 10.1158/1055-9965.EPI-12-0173. [PubMed: 22736789].
  • 16. Yu DC, Li QG, Ding XW, Ding YT. Circulating microRNAs: potential biomarkers for cancer. Int J Mol Sci. 2011;12(3):2055-63. doi: 10.3390/ijms12032055. [PubMed: 21673939].
  • 17. Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res. 2011;71(13):4443-53. doi: 10.1158/0008-5472.CAN-11-0608. [PubMed: 21586611].
  • 18. Azizian A, Gruber J, Ghadimi BM, Gaedcke J. MicroRNA in rectal cancer. World J Gastrointest Oncol. 2016;8(5):416-26. doi: 10.4251/wjgo.v8.i5.416. [PubMed: 27190581].
  • 19. Slezak-Prochazka I, Kluiver J, de Jong D, Smigielska-Czepiel K, Kortman G, Winkle M, et al. Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma. Oncotarget. 2016;7(3):2391-400. doi: 10.18632/oncotarget.6165. [PubMed: 26497687].
  • 20. Hemmatzadeh M, Mohammadi H, Jadidi-Niaragh F, Asghari F, Yousefi M. The role of oncomirs in the pathogenesis and treatment of breast cancer. Biomed Pharmacother. 2016;78:129-39. doi: 10.1016/j.biopha.2016.01.026. [PubMed: 26898434].
  • 21. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010;70(8):3119-27. doi: 10.1158/0008-5472.CAN-09-4250. [PubMed: 20354188].
  • 22. Persson JL. miR-155 meets the JAK/STAT pathway. Cell Cycle. 2013;12(14):2170. doi: 10.4161/cc.25548. [PubMed: 23803728].
  • 23. Bacci M, Giannoni E, Fearns A, Ribas R, Gao Q, Taddei ML, et al. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. Cancer Res. 2016;76(6):1615-26. doi: 10.1158/0008-5472.CAN-15-2038. [PubMed: 26795347].
  • 24. Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010;12(6):R90. doi: 10.1186/bcr2766. [PubMed: 21047409].
  • 25. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119(3):586-93. doi: 10.1016/j.ygyno.2010.07.021. [PubMed: 20801493].
  • 26. Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One. 2012;7(10). e47003. doi: 10.1371/journal.pone.0047003. [PubMed: 23071695].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader